Company news

Intellia Therapeutics, Inc. news in 2021

Intellia Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

December 19, 2021

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

December 12, 2021

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

November 21, 2021

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

November 4, 2021

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

November 3, 2021

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

October 27, 2021

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

October 20, 2021

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress

October 19, 2021

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

October 12, 2021

Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress

October 11, 2021

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

October 5, 2021

Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference

September 26, 2021

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

September 15, 2021

Intellia Therapeutics to Present at September Healthcare Investor Conferences

August 30, 2021

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

August 4, 2021

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

July 28, 2021

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

July 1, 2021

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

June 25, 2021

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

June 23, 2021

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

June 21, 2021

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

June 3, 2021

Intellia Therapeutics Announces First Quarter 2021 Financial Results

May 5, 2021

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates

April 28, 2021

Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting

April 26, 2021

Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors

April 11, 2021

Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis

March 29, 2021

Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors

March 24, 2021

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

March 9, 2021

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results

February 24, 2021

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates

February 17, 2021

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021

January 6, 2021

Decks in 2021